Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 32K
2: EX-99.1 Miscellaneous Exhibit HTML 17K
6: R1 Cover Page HTML 46K
9: XML IDEA XML File -- Filing Summary XML 12K
7: XML XBRL Instance -- wst-20220222_htm XML 22K
8: EXCEL IDEA Workbook of Financial Reports XLSX 6K
4: EX-101.LAB XBRL Labels -- wst-20220222_lab XML 67K
5: EX-101.PRE XBRL Presentations -- wst-20220222_pre XML 33K
3: EX-101.SCH XBRL Schema -- wst-20220222 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K
11: ZIP XBRL Zipped Folder -- 0001628280-22-004277-xbrl Zip 33K
Registrant’s telephone number, including area code: i610-i594-2900
Not
Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading Symbol
Name of each exchange on which registered
iCommon Stock, par value $0.25 per share
iWST
iNew
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
After
20 years of dedicated service, Patrick Zenner informed West Pharmaceutical Services, Inc. (the “Company”) on February 22, 2022, of his intention to retire and not to stand for re-election as Chairman to the Company’s Board of Directors ("Board") at the next Annual Meeting of Shareholders, scheduled to be held on May 24, 2022 (the “Annual Meeting”). Mr. Zenner will continue to actively serve on the Company’s Board until the Annual Meeting. Mr. Zenner has informed the Company that there is no disagreement between him and the
Company on any matter relating to its operations, polices or practices.
Eric M. Green, President and Chief Executive Officer ("CEO"), will assume the additional responsibility of Chair of the Company's Board upon Mr. Zenner's retirement. In accordance with West's corporate governance principles, when the roles of Chair and CEO are combined, the Board will appoint a Lead Independent Director. Accordingly, West has appointed Paolo Pucci as the Lead Independent Director for the Board of Directors, effective at the Annual Meeting. Mr. Pucci will be the primary liaison between Mr. Green and the Board of Directors with ability to call and lead independent sessions with the Board.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
The cover page from the Company’s Current Report on Form 8-K, dated February 22, 2022, formatted in Inline XBRL.
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
